Madrigal Pharmaceuticals Stock Total Debt
| MDGL Stock | USD 329.24 12.15 3.83% |
Madrigal Pharmaceuticals fundamentals help investors to digest information that contributes to Madrigal Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Madrigal Stock. The fundamental analysis module provides a way to measure Madrigal Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Madrigal Pharmaceuticals stock.
Total Debt To Capitalization is expected to rise to 0.44 this year. Madrigal | Total Debt |
Madrigal Pharmaceuticals Company Total Debt Analysis
Madrigal Pharmaceuticals' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Madrigal Pharmaceuticals Total Debt | 117.19 M |
Most of Madrigal Pharmaceuticals' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Madrigal Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Madrigal Total Debt Driver Correlations
Understanding the fundamental principles of building solid financial models for Madrigal Pharmaceuticals is extremely important. It helps to project a fair market value of Madrigal Stock properly, considering its historical fundamentals such as Total Debt. Since Madrigal Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Madrigal Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Madrigal Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Madrigal Total Debt Historical Pattern
Today, most investors in Madrigal Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Madrigal Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Madrigal Pharmaceuticals total debt as a starting point in their analysis.
Madrigal Pharmaceuticals Total Debt |
| Timeline |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Madrigal Net Debt
Net Debt |
|
Based on the latest financial disclosure, Madrigal Pharmaceuticals has a Total Debt of 117.19 M. This is 95.74% lower than that of the Biotechnology sector and 63.92% lower than that of the Health Care industry. The total debt for all United States stocks is 97.8% higher than that of the company.
Madrigal Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Madrigal Pharmaceuticals' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Madrigal Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Madrigal Pharmaceuticals by comparing valuation metrics of similar companies.Madrigal Pharmaceuticals is currently under evaluation in total debt category among its peers.
Madrigal Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Madrigal Pharmaceuticals from analyzing Madrigal Pharmaceuticals' financial statements. These drivers represent accounts that assess Madrigal Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Madrigal Pharmaceuticals' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 1.4B | 1.7B | 1.4B | 5.0B | 4.3B | 4.5B | |
| Enterprise Value | 1.4B | 1.7B | 1.4B | 4.7B | 4.3B | 4.6B |
Madrigal Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Madrigal Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Madrigal Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Madrigal Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Madrigal Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Madrigal Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Madrigal Pharmaceuticals' value.| Shares | Geode Capital Management, Llc | 2024-06-30 | 399.9 K | Artisan Partners Limited Partnership | 2024-06-30 | 345.1 K | Rock Springs Capital Management Lp | 2024-06-30 | 245.5 K | Bank Of America Corp | 2024-06-30 | 239.6 K | Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-06-30 | 187.4 K | Braidwell Lp | 2024-09-30 | 183.8 K | Ubs Group Ag | 2024-06-30 | 173.2 K | Goldman Sachs Group Inc | 2024-06-30 | 171.5 K | Armistice Capital, Llc | 2024-06-30 | 150 K | Hhg Plc | 2024-06-30 | 2.5 M | Paulson & Company Inc | 2024-09-30 | 2 M |
Madrigal Fundamentals
| Return On Equity | -1.3 | ||||
| Return On Asset | -0.52 | ||||
| Operating Margin | (1.87) % | ||||
| Current Valuation | 6.04 B | ||||
| Shares Outstanding | 21.81 M | ||||
| Shares Owned By Insiders | 14.80 % | ||||
| Shares Owned By Institutions | 85.20 % | ||||
| Number Of Shares Shorted | 4.53 M | ||||
| Price To Earning | (13.96) X | ||||
| Price To Book | 8.90 X | ||||
| Price To Sales | 90.03 X | ||||
| EBITDA | (379.97 M) | ||||
| Net Income | (373.63 M) | ||||
| Cash And Equivalents | 211.77 M | ||||
| Cash Per Share | 12.38 X | ||||
| Total Debt | 117.19 M | ||||
| Debt To Equity | 0.59 % | ||||
| Current Ratio | 2.55 X | ||||
| Book Value Per Share | 35.64 X | ||||
| Cash Flow From Operations | (324.23 M) | ||||
| Short Ratio | 13.46 X | ||||
| Earnings Per Share | (25.02) X | ||||
| Target Price | 372.2 | ||||
| Number Of Employees | 376 | ||||
| Beta | -0.47 | ||||
| Market Capitalization | 6.92 B | ||||
| Total Asset | 640.55 M | ||||
| Retained Earnings | (1.34 B) | ||||
| Working Capital | 518.73 M | ||||
| Current Asset | 363.58 K | ||||
| Current Liabilities | 49.28 M | ||||
| Net Asset | 640.55 M |
About Madrigal Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Madrigal Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Madrigal Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Madrigal Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Madrigal Pharmaceuticals Piotroski F Score and Madrigal Pharmaceuticals Altman Z Score analysis. For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Madrigal Pharmaceuticals. If investors know Madrigal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Madrigal Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (25.02) | Revenue Per Share 3.705 | Return On Assets (0.52) | Return On Equity (1.30) |
The market value of Madrigal Pharmaceuticals is measured differently than its book value, which is the value of Madrigal that is recorded on the company's balance sheet. Investors also form their own opinion of Madrigal Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Madrigal Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Madrigal Pharmaceuticals' market value can be influenced by many factors that don't directly affect Madrigal Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Madrigal Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Madrigal Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Madrigal Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.